Comparative Pharmacology
Head-to-head clinical analysis: OFEV versus QINLOCK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OFEV versus QINLOCK.
OFEV vs QINLOCK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nintedanib is a tyrosine kinase inhibitor that blocks the activity of fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), thereby inhibiting fibroblast proliferation, migration, and transformation, and reducing extracellular matrix deposition.
Ripretinib is a switch-control tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) kinase signaling. It binds to both the switch pocket and the activation loop of KIT and PDGFRA, preventing kinase activation and inhibiting downstream signaling pathways involved in tumor cell proliferation and survival.
150 mg orally twice daily, taken with food.
150 mg orally once daily with food, until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 38 hours (range 30–48 hours) at steady state, supporting once-daily dosing.
Terminal elimination half-life is approximately 15 hours (range 11–20 hours) in patients with advanced GIST. This supports twice-daily dosing.
Primarily biliary/fecal (~93.4% of total radioactivity recovered in feces), renal excretion is minor (~0.6% unchanged in urine).
Primarily hepatic metabolism, with <1% excreted unchanged in urine. Fecal excretion accounts for approximately 80% of the administered dose, with renal excretion of unchanged drug being minimal (<1%).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor